Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.

Competing Interests: Conflict of interest: None for T. Nguyen-Khoa, A. Hatton, D. Drummond, L. Aoust, J. Schlatter, S. Ramel, S. Kiefer, E. Gachelin, L. Cosson, A. Gabsi, N. Remus, M. Benhamida, A. Hadchouel, A. Munck and E. Girodon. Grants or contracts: I. Fajac from AbbVie, Boehringer Ingelheim and Vertex Pharmaceuticals. Payment or honoraria for lectures and presentations: C. Martin from Zambon, Chiesi, Vertex and AstraZeneca; I. Fajac and I. Sermet-Gaudelus from Vertex Pharmaceuticals. Support for attending meetings and/or travel: C. Martin from Sanofi. Participated on a data safety monitoring board or advisory board: C. Martin for Zambon and GSK; N. Stremler for Vertex; I. Fajac and I. Sermet-Gaudelus for Vertex, Boehringer Ingelheim and Kither Biotech. Leadership or fiduciary role in other board, society, committee or advocacy group: I. Fajac for European Cystic Fibrosis Society.